249 related articles for article (PubMed ID: 11012557)
1. A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers.
Bani M; Colantoni A; Guillaume M; Macchi F; Moroni G; Persiani S
Br J Clin Pharmacol; 2000 Oct; 50(4):338-49. PubMed ID: 11012557
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of dual ACE/NEP inhibitor GW660511X in mild-to-moderate hypertensive patients.
Johnson AG; Pearce GL; Danoff TM
J Hum Hypertens; 2006 Jul; 20(7):496-503. PubMed ID: 16543907
[TBL] [Abstract][Full Text] [Related]
3. The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin.
Rastegar MA; Marchini F; Morazzoni G; Vegh A; Papp JG; Parratt JR
Br J Pharmacol; 2000 Feb; 129(4):671-80. PubMed ID: 10683191
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects.
Liao WC; Vesterqvist O; Delaney C; Jemal M; Ferreira I; Ford N; Swanson B; Uderman H
Br J Clin Pharmacol; 2003 Oct; 56(4):395-406. PubMed ID: 12968984
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans.
Azizi M; Bissery A; Peyrard S; Guyene TT; Ozoux ML; Floch A; Ménard J
Clin Pharmacol Ther; 2006 Jan; 79(1):49-61. PubMed ID: 16413241
[TBL] [Abstract][Full Text] [Related]
6. Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers.
Rousso P; Buclin T; Nussberger J; Décosterd LA; La Roche SD; Brunner-Ferber F; Brunner HR; Biollaz J
J Hypertens; 1999 Mar; 17(3):427-37. PubMed ID: 10100082
[TBL] [Abstract][Full Text] [Related]
7. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
8. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats.
Daull P; Benrezzak O; Arsenault D; Pheng LH; Blouin A; Cayer J; Beaudoin M; Belleville K; Sirois P; Nantel F; Jeng AY; Battistini B
Am J Hypertens; 2005 Dec; 18(12 Pt 1):1606-13. PubMed ID: 16364833
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
[TBL] [Abstract][Full Text] [Related]
13. Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug.
Balavoine F; Azizi M; Bergerot D; De Mota N; Patouret R; Roques BP; Llorens-Cortes C
Clin Pharmacokinet; 2014 Apr; 53(4):385-95. PubMed ID: 24337978
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study.
Morain P; Robin JL; De Nanteuil G; Jochemsen R; Heidet V; Guez D
Br J Clin Pharmacol; 2000 Oct; 50(4):350-9. PubMed ID: 11012558
[TBL] [Abstract][Full Text] [Related]
15. Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition.
Cawello W; Boekens H; Waitzinger J; Miller U
Int J Clin Pharmacol Ther; 2002 Jan; 40(1):9-17. PubMed ID: 11837383
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability of repeated oral administration of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteers.
Rousso P; Buclin T; Nussberger J; Brunner-Ferber F; Brunner HR; Biollaz J
Eur J Clin Pharmacol; 2000 Jan; 55(10):749-54. PubMed ID: 10663454
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and biochemical efficacy of idrapril calcium, a novel ACE inhibitor, after multiple oral administration in humans.
Wyld PJ; Grant J; Lippi A; Criscuoli M; Del Re G; Subissi A
Br J Clin Pharmacol; 1994 Nov; 38(5):421-5. PubMed ID: 7893583
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects.
Duchin KL; Waclawski AP; Tu JI; Manning J; Frantz M; Willard DA
J Clin Pharmacol; 1991 Jan; 31(1):58-64. PubMed ID: 1646240
[TBL] [Abstract][Full Text] [Related]
20. Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake.
Azizi M; Lamarre-Cliche M; Labatide-Alanore A; Bissery A; Guyene TT; Ménard J
J Am Soc Nephrol; 2002 Oct; 13(10):2454-63. PubMed ID: 12239234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]